Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Reduction of Postherpetic Neuralgia in Herpes Zoster
- Conditions
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Center for Clinical Studies, Texas
- Target Recruit Count
- 133
- Registration Number
- NCT01250561
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?
- Conditions
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 60
- Registration Number
- NCT01176409
- Locations
- 🇨🇦
Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
Valacyclovir 1000 mg Tablet Under Fasting Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2010-06-23
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT01149499
- Locations
- 🇺🇸
PRACS Institute, Ltd., East Grand Forks, Minnesota, United States
Valacyclovir 1000 mg Tablet Under Fed Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 36
- Registration Number
- NCT01149460
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
- Conditions
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- University of Washington
- Registration Number
- NCT01059084
Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- G.V. (Sonny) Montgomery VA Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01037621
- Locations
- 🇺🇸
G.V. Sonny Montgomery VA Medical Center, Jackson, Mississippi, United States
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 32
- Registration Number
- NCT01026454
- Locations
- 🇰🇪
Thika Partners in Prevention, Thika, Kenya
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
- Conditions
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- University of Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT00946556
- Locations
- 🇨🇦
Women's Health In Women's Hands, Toronto, Ontario, Canada
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
- Conditions
- Interventions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT00900783
Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 442
- Registration Number
- NCT00870441
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.